Le Lézard
Classified in: Health
Subjects: PDT, SCZ

BioPhotas, Inc. Launches the Newest Model of the Celluma Series



ANAHEIM, Calif., Jan. 3, 2018 /PRNewswire/ -- BioPhotas, Inc. announces the commercial introduction of the Celluma HOME, a fourth model in the Celluma Series of light therapy devices. Offered at an introductory price of $599.00, the Celluma HOME specifically addresses the challenges of Baby Boomers who struggle with wrinkles, aches and pain. FDA-cleared for over-the-counter purchase, the Celluma HOME treats eight separate aging challenges faced by the Baby Boomer, including full face wrinkles, arthritis, muscle and joint pain, muscle spasms and poor blood circulation.

Commenting on the launch of the Celluma HOME, Patrick Johnson, President & Chief Executive Officer for BioPhotas said, "From the very start, our goal at BioPhotas was to bring an FDA-cleared medical device directly to the consumer at home with the efficacy of large professional panels, but with the affordability of small hand-held devices. We believe we have achieved this with the Celluma HOME. Designed to treat a wide range of skin, muscle and joint conditions, anywhere on the body, the Celluma HOME gives the consumer the benefit of multiple hand-held devices in a single light panel with a significantly larger in treatment area."  

The Celluma HOME delivers blue, red and near-infrared light energy to safely address a wide variety of musculoskeletal and dermatological conditions. Each wavelength is absorbed by different molecules which act as a signaling mechanism for different cellular processes. With a treatment area that measures 14" by 6", the Celluma HOME is several times larger than typical hand-held light therapy devices. The Celluma's patented shape-taking light panel facilitates effective energy absorption by tissue by molding closely to any apart of the body, producing more efficient outcomes. 

The Celluma Series of light therapy devices is protected by both United States and Foreign utility patents and is CE-marked as a Dermal Wound Healing device. Further commenting on the launch of the Celluma HOME, Mr. Johnson noted, "[T]he Celluma HOME is a two-mode device designed specifically for the Baby Boomer who is interested in looking better and feeling better, and who wants to address those desires in the convenience of their own home." 

About BioPhotas, Inc.
In providing unique devices founded on NASA-developed technology and backed by clinical studies, BioPhotas is bringing to market safe, effective and affordable devices that unlock the clinical power of biophotonics. BioPhotas develops and markets devices for healthcare providers and consumers that conveniently treat a variety of skin, muscle and joint conditions. For more information about the Celluma please visit www.biophotas.com.

CONTACT:                                                                  
Patrick Johnson ? CEO
BioPhotas, Inc.
188219@email4pr.com 
7149780080

SOURCE BioPhotas, Inc.


These press releases may also interest you

at 07:03
Microbix Biosystems Inc. (Microbix®), an innovator of biological products and technologies, announces the expansion of its quality assessment product family, with 48 new products being completed and made available for sale under its PTDxtm and...

at 07:03
Purepoint Uranium Group Inc. (the "Company" or "Purepoint") today reported the completion of the first seven holes of the 2017/2018 Winter drill program at the Hook Lake JV, a project owned jointly by Cameco Corp. (39.5%), AREVA Resources Canada...

at 07:00
Choomtm  is pleased to announce it has signed a Letter of Intent ("LOI") to acquire its second, advanced-stage cannabis production licence applicant ("Target") under Health Canada's Access to Cannabis for Medical Purposes Regulations (ACMPR). The...

at 07:00
Neovasc Inc. ("Neovasc" or the "Company") today reported its Neovasc Reducertm ("Reducer") was featured in a "live case" broadcast to more than 800 participants at the Kardiologie Symposium 2018 held in Berlin, Germany.  The successful live case was...

at 07:00
Riffyn, a Global Provider of R&D Software, announced the opening of its office in Boston, MA to meet the rapid growth of its global customer base in the Eastern US and Europe. The office provides sales, scientific consulting and application support...

at 07:00
WallStEquities.com strives to bring the best free research to the investment community.  Today we are offering reports on RARE, REGN, SGEN, and SGMO which can be accessed for free by signing up to www.wallstequities.com/registration....




News published on 3 january 2018 at 15:37 and distributed by: